Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 7/20 | 0.36 |
| ▸ | RBP4 | P02753 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3325005 | 0.88 | SLC6A4 (0.41) | KDM4EALDH1A1RBP4KMT2AMAPT | |
| SCHEMBL3325393 | 0.88 | SLC6A4 (0.41) | KDM4EALDH1A1RBP4KMT2AMAPT | |
| SCHEMBL3327586 | 0.88 | SLC6A4 (0.41) | KDM4EALDH1A1RBP4KMT2AMAPT | |
| SCHEMBL3329458 | 0.77 | KDM4E (0.36) | KDM4EALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4948250 | 0.75 | SLC6A4 (0.47) | KDM4EALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4948245 | 0.75 | SLC6A4 (0.47) | KDM4EALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3330887 | 0.70 | EPHA2 (0.45) | KDM4EALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL9996620 | 0.67 | REN (0.43) | CYP1A2CYP2C9CYP2C19KMT2AMAPT | |
| SCHEMBL9996622 | 0.67 | REN (0.43) | CYP1A2CYP2C9CYP2C19KMT2AMAPT | |
| SCHEMBL3329277 | 0.66 | SMN1; SMN2 (0.43) | ALDH1A1CYP1A2CYP2C9CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | FISH PAUL VINCENT | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | OPRL1, UGT1A1, HTR3B | KDM4E 1680/4885ALDH1A1 690/4885CYP1A2 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.